Clinical trial design and development work group within the quantitative imaging network

Ella F. Jones, John M. Buatti, Hui Kuo Shu, Richard L. Wahl, Brenda F. Kurland, Hannah M. Linden, David A. Mankoff, Daniel L. Rubin, Darrell Tata, Robert J. Nordstrom, Lubomir Hadjiyski, Matthias Holdhoff, Lawrence H. Schwartz

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


The Clinical Trial Design and Development Working Group within the Quantitative Imaging Network focuses on providing support for the development, validation, and harmonization of quantitative imaging (QI) methods and tools for use in cancer clinical trials. In the past 10 years, the Group has been working in several areas to identify challenges and opportunities in clinical trials involving QI and radiation oncology. The Group has been working with Quantitative Imaging Network members and the Quantitative Imaging Biomarkers Alliance leadership to develop guidelines for standardizing the reporting of quantitative imaging. As a validation platform, the Group led a multireader study to test a semi-automated positron emission tomography quantification software. Clinical translation of QI tools cannot be possible without a continuing dialogue with clinical users. This article also highlights the outreach activities extended to cooperative groups and other organizations that promote the use of QI tools to support clinical decisions.

Original languageEnglish
Pages (from-to)60-64
Number of pages5
JournalTomography (Ann Arbor, Mich.)
Issue number2
StatePublished - Jun 2020


  • Clinical Trial Design and Development (CTDD)
  • Quantitative Imaging Network (QIN)


Dive into the research topics of 'Clinical trial design and development work group within the quantitative imaging network'. Together they form a unique fingerprint.

Cite this